KT-579 / Kymera Therap - LARVOL DELTA

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases (GlobeNewswire) - "KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA; IND-enabling studies are ongoing with Phase 1 testing expected to begin in early 2026."

New P1 trial • Preclinical • Immunology • Lupus • Rheumatoid Arthritis